[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477999":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":37,"locations":43,"responsibleParty":60,"collaborators":10,"id":62,"slug":10,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":75,"briefSummary":78,"conditions":79,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8,13,18],{"label":9,"type":6,"description":10,"interventionNames":11},"Postoperative NSAIDs",null,[12],"Drug: Postoperative flurbiprofen axetil",{"label":14,"type":15,"description":10,"interventionNames":16},"Preemptive analgesia followed by Postoperative NSAIDs","EXPERIMENTAL",[17,12],"Drug: Preemptive flurbiprofen axetil",{"label":19,"type":15,"description":10,"interventionNames":20},"Postoperative patient-controlled analgesia pump",[21],"Device: Patient-controlled analgesia pump",[23,28,32],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DRUG","Preemptive flurbiprofen axetil","50mg once，30min before induction anesthesia",[14],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"Postoperative flurbiprofen axetil","50mg bid",[9,14],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"DEVICE","Patient-controlled analgesia pump","Sufentanil 2.5 μg\u002Fkg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml\u002Fh, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.",[19],[38],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"zhu zhixiang","CONTACT","13311131231","zhuzhixiang2010@163.com",[44],{"facility":45,"status":46,"city":47,"state":10,"zip":10,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Cancer Hospital Chinese Academy of Medical Sciences","RECRUITING","Beijing","China",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56],{"name":57,"role":40,"phone":58,"phoneExt":10,"email":59},"Yin Li, MD","861087788052","liyin@cicams.ac.cn",{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100477999",false,"NCT05504265","Perioperative Analgesia Modes in Minimally Invasive Esophagectomy","Comparison of Efficacy and Safety of Different Analgesic Modes in Minimally Invasive Esophagectomy for Esophageal Cancer","Inclusion Criteria:\n\n* 18-75 years;\n* Patients underwent laparoscopic and thoracoscopic or robotic-assisted minimally invasive esophagectomy ;\n* Informed consent.\n\nExclusion Criteria:\n\n* Has a history of cholecystitis or urolithiasis within 3 months;\n* Has a history of atherothrombosis (peripheral arterial disease), stroke, myocardial infarction;\n* With lung diseases, such as pneumonia, atelectasis, emphysema, pulmonary bullae, etc;\n* Preoperative cardiac function grade ≥ III or coronary artery stenosis;\n* Preoperative indwelling of a thoracic drainage tube;\n* Long-term heavy drinker(heavy drinking was defined as follows: for men, consuming more than 4 drinks on any day or more than 14 drinks per week; For women, consuming more than 3 drinks on any day or more than 7 drinks per week);\n* Opioid-tolerant patients(defined as those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid);\n* With painful skin complications, such as rashes and blisters;\n* Conversion to open surgery;\n* The postoperative ventilation function was limited, or the duration of endotracheal intubation was more than 24h.","ALL","18 Years","75 Years",{"count":72,"type":73},102,"ESTIMATED","INTERVENTIONAL",[76,77],"PHASE2","PHASE3","This study was designed to compare analgesic efficacy and safety of different perioperative analgesic modes in minimally invasive esophagectomy for esophageal cancer.",[80,81,82,83,84],"Esophageal Cancer","Perioperative Analgesia","NSAIDs","Opioid","Patient-controlled Analgesia","2025-03-17",{"date":87,"type":88},"2025-03-20","ACTUAL",{"date":90,"type":88},"2022-10-10",{"date":92,"type":73},"2025-12-20",{"name":5,"class":6},1]